Plain-English translation of NCT03619850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to treat iron deficiency anemia in children with chronic kidney disease. is given through IV infusions and is being compared to another iron treatment called to see which works better and is safer for young patients whose kidneys aren't working properly.
Children with chronic kidney disease often develop low iron levels, which makes them feel tired and can harm their health. This trial is testing whether this medication might be a better treatment option than what is currently available.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new medication or the standard iron treatment over about 5 weeks. You'll have a 2-week screening period where doctors will run tests to make sure you qualify, then a 5-week treatment period where you'll receive IV infusions. Depending on which group you're in, you'll either get two doses of the new medication spaced a few days apart, or multiple doses of the standard treatment given either during dialysis sessions or as separate infusions.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States